Compensation and Remuneration - The total pre-tax compensation for the company's directors and senior management amounted to 1,131.48 million CNY[1]. - The board of directors reviewed and approved the remuneration scheme for directors and senior management for the 2022 fiscal year[6]. - The company distributed cash dividends of ¥33,587.92 million (including tax) during the reporting period, with cumulative cash dividends over the last three years reaching ¥81,671.68 million, representing 35.12% of the net profit in the same period[88]. Internal Controls and Audits - The company conducted an internal control audit, identifying key risk areas and providing corrective measures based on audit findings[17]. - The audit report on internal controls received a standard unqualified opinion, indicating no significant deficiencies in non-financial reporting[20]. - There were no significant defects reported in financial or non-financial internal controls during the reporting period[40]. - The company has not identified any risks during the supervisory activities of the supervisory board in the reporting period[8]. Environmental Compliance and Sustainability - The company reported a significant focus on environmental compliance, with no major environmental incidents occurring throughout the year[34]. - The company has implemented automatic, manual, and periodic monitoring for pollution control, ensuring compliance with national pollution monitoring platforms[32]. - The company has committed to continuous improvement in environmental risk management and has established emergency response measures for environmental incidents[34]. - The company has complied with various environmental protection laws and regulations, ensuring adherence to national standards[43]. - The company has maintained a focus on sustainable practices, aligning its operations with environmental protection initiatives[36]. Research and Development - The company has invested significantly in R&D and project construction to enhance its core competitiveness amid a challenging external environment[67]. - R&D expenses for the reporting period amounted to ¥53,291.97 million, reflecting a year-on-year increase of 10%[99]. - The company has established R&D centers in all three major business segments, with a total of 1,026 R&D personnel, including 46 PhDs and 220 Master's degree holders[104]. - The company emphasizes a continuous increase in R&D investment to enhance its research capabilities and innovation[104]. - The company has increased its R&D personnel by 16.72% from 879 in 2021 to 1,026 in 2022, with the proportion of R&D staff rising from 14.33% to 15.11%[203]. Financial Performance - The company's total revenue for 2022 reached ¥10,544,905,377.17, representing a year-on-year increase of 17.92% compared to ¥8,942,618,232.82 in 2021[93]. - Net profit attributable to shareholders for 2022 was ¥989,173,675.64, a 3.52% increase from ¥955,550,170.21 in 2021[139]. - The net cash flow from operating activities reached ¥1,326,107,316.20, a significant increase of 116.77% compared to ¥611,748,728.68 in 2021[139]. - Total assets at the end of 2022 amounted to ¥12,016,599,023.18, reflecting a 32.86% increase from ¥9,044,671,981.35 at the end of 2021[139]. - The company's basic earnings per share for 2022 was ¥0.8425, up 3.91% from ¥0.8108 in 2021[139]. Market and Business Operations - The company primarily engages in the production of pharmaceutical raw materials, CDMO services, and formulations, adhering to environmental protection laws and industry standards[23]. - The company has a global marketing network covering over 70 countries and regions, with domestic market presence in all provinces except Qinghai and Tibet[64]. - The company's CDMO business revenue was composed of 87% from foreign clients and 13% from domestic clients, with a significant growth in domestic revenue in 2022[70]. - The number of ongoing CDMO projects increased by 62% year-on-year to 524, with 298 projects in the R&D stage (up 108%) and 226 in the commercialization stage (up 26%)[70]. - The company has established a management structure that includes three business divisions: API, CDMO, and FDF, aimed at enhancing operational efficiency[176]. Corporate Governance - The company has developed a self-assessment process for corporate governance, enhancing transparency and accountability[42]. - The company has actively engaged with stakeholders, including shareholders and suppliers, to align business practices with their interests[36]. - The company held its 2021 annual general meeting with a participation rate of 58.13% on March 31, 2022, and disclosed the resolutions on April 1, 2022[198]. - The company conducted its first extraordinary general meeting of 2022 with a participation rate of 54.82% on December 27, 2022, with resolutions disclosed on December 28, 2022[198].

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司投资者关系活动记录表 编号：1 | --- | --- | |------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司投资者关系活动记录表 编号：1 | --- | --- | |------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000739 证券简称：普洛药业 编号：2 | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司投资者关系活动记录表 编号：1 | --- | --- | |------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2020-03 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司投资者关系活动记录表 编号：1 | --- | --- | |------------------------------|--------------------------------------------------------------------------------------------------------------------| | 投资者关系活 动类别 | □ 其他 （投资者沟通见面会） | | 参与单位名称 及人员姓名 | 个人投资者 潭伟鸿 | | | 渤商控股集团 潘粤生 | | | 横华国际证券有限公司 周亚科 | | | 横华国际证券有限公司 许支睿 | | | 横华国际证券有限公司 李玲芳 | | | 横华国际证券有限公司 陈晓毅 | | | 南华期货股份有限公司 凌乐敏 | | | | | 时间 | 2017 年 9 月 22 日上午 10:00-11:00 点 | | 地点 | 普洛药业会议室 | | 上市公司接待 人员姓名 | 葛向全、楼云娜 | | 投资者关系活 动主要内容介 绍 | 一、介绍公司 ...

编号：2020-01 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-----------------------|------------------------------------------------------| | 投资者关系活动 \n类别 | R 特定对象调研 | | | 国金证券（朱明睿）；川财证券（周豫）；东兴证券（许 | | 参与单位名称及 | 睿）；上海茂典资产（董阳）；深圳望正资产（高敏）；杭 | | 人员姓名 | 州睿银投资（许磊）；上海沣杨资产（张秀磊）；东方红资 | | | 管（刘中群） | | 时间 | 2020 年 1 月 15 日 14:30-15:30 | | 地点 | 公司会议室 | | 上市公司接待人 | 董事会秘书、副总经理周玉旺先生 | | 员姓名 | 证券事务代表 楼云娜女士 | | 投资者关系活动 | 首先向投资者简要介绍了公司的业务情况，并就公司生 | | 主要内容介绍 | 产经营等相关事项进行了沟通与交流，主要内容如下： | | | 1 、请问公司未来对生产线的规划如何？ | | ...

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 编号：2020-02 | --- | --- | |-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | 特定对象调研 | | 参与单位名称 | 民生证券 孙建、曹聪聪；华商基金 蔡峰；华安基金 裘倩倩、崔莹；汇添富 基金 张韡、翁强；广发基金 王瑞冬；富国基金 厉叶淼；国泰基金 杨钟男； | | 及人员姓名 | 工银瑞信 李善欣；安信基金 池陈森；华宝基金 窦金虎；长 ...